00:12 , Jun 15, 2019 |  BC Extra  |  Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
22:27 , Jun 14, 2019 |  BC Extra  |  Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

Flatiron Health Inc. hired Michael Vasconcelles as CMO. Vasconcelles, who was CMO of Unum Therapeutics Inc. (NASDAQ:UMRX), succeeds Amy Abernethy, who left to join FDA as principal deputy commissioner early this year. The Roche (SIX:ROG;...
21:57 , Jun 14, 2019 |  BC Extra  |  Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells   The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in...
00:52 , Jun 11, 2019 |  BC Extra  |  Company News

June 10 Company Quick Takes: Roche's Spark takeover delayed again; plus Insys, China audits, Novavax and more

More delays for Roche's Spark acquisition, plus U.K. investigation   After at least three previous delays, Roche (SIX:ROG; OTCQX:RHHBY) has extended its deadline to acquire Spark Therapeutics Inc. (NASDAQ:ONCE) to July 31 from June 14...
00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
23:58 , Jun 5, 2019 |  BC Extra  |  Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
23:09 , Jun 4, 2019 |  BC Extra  |  Company News

Arvinas adds to momentum with Bayer deal for protein degraders

Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes...
20:36 , May 31, 2019 |  BC Extra  |  Financial News

New IPO filings include Adaptive, Morphic

Immunosequencing company Adaptive and integrin company Morphic each filed for IPOs on NASDAQ Thursday, while antipsychotic therapy developer Karuna revealed details of its planned listing on the exchange on Friday. Adaptive Biotechnologies Corp. (Seattle, Wash.)...
22:01 , May 30, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi hires Atara's Berger; plus Emmaus, enGene and more

Two days after Atara Biotherapeutics Inc. (NASDAQ:ATRA) announced Dietmar Berger was departing as global head of R&D, Sanofi (Euronext:SAN; NASDAQ:SNY) has announced he will oversee its clinical portfolio as head of development. Prior to his...